Targeted Potassium Levels, Mineralocorticoid Receptor Antagonism, and Cardiovascular Outcomes in Patients With High Arrhythmic Risk: A Reinterpretation of the POTCAST Trial. - Marques P; Neves JS; Ferreira JP (Journal of cardiac failure, 2026)